Robert Flath

Robert Flath currently serves as the Head of FP&A at Longboard Pharmaceuticals since September 2023. Prior to this role, Robert held the position of Senior Director of Finance at Bristol Myers Squibb from August 2022 to May 2023, and at Turning Point Therapeutics from June 2021 to August 2022. Robert's career also includes significant experience at Crinetics Pharmaceuticals as Director of Finance (August 2018 - June 2021) and at Regulus Therapeutics as Senior Manager II, FP&A (August 2015 - July 2018). Earlier roles include Senior Financial Analyst positions at Thermo Fisher Scientific (February 2014 - August 2015) and Life Technologies (September 2010 - January 2014), as well as a Business Financial Analyst position following NXP's acquisition of Freescale Semiconductor (June 2006 - August 2009). Robert holds both a Master's and Bachelor's degree in Finance from the University of Arizona.